Glomerular Disease in Pregnancy

Chapter

Abstract

Multiple glomerular diseases may affect women of childbearing age. The relationship between glomerular disease and pregnancy is complex and should be approached from two major standpoints: the effects of pregnancy on maternal disease activity and progression and effects of the disease and related medical therapy on the developing fetus. Glomerular disease may be active or quiescent at conception, may flare during pregnancy, or may occur de novo during pregnancy.

Adverse fetal outcomes (spontaneous abortion, prematurity, intrauterine growth retardation) and maternal outcomes (preeclampsia, renal disease flare) are common, particularly in patients with active disease and those with advanced renal insufficiency. Consequently, irrespective of the underlying etiology, remission of renal disease for >6 months prior to conception is recommended. The risk for progression is increased for patients with established renal insufficiency with creatinine values >1.4 mg/dL.

The differential diagnosis of worsening proteinuria, which commonly occurs during the third trimester in all proteinuric renal diseases, should include renal disease flare and preeclampsia, a pregnancy-specific condition clinically characterized by hypertension and proteinuria. If indicated, a renal biopsy can be safely performed prior to 32 weeks gestation in women with adequately controlled blood pressure and in the absence of coagulation abnormalities. The goal of therapy during pregnancy is control of disease activity, both renal and systemic, with medications that are relatively safe for a growing fetus. Consequently, the optimal management of these patients crosses specialties and should include a nephrologist, obstetrician, and, commonly, a rheumatologist.

Keywords

Systemic Lupus Erythematosus Renal Biopsy Thrombotic Thrombocytopenic Purpura Membranous Nephropathy Glomerular Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Fischer MJ. Chronic kidney disease and pregnancy: maternal and fetal outcomes. Adv Chronic Kidney Dis. 2007;14(2):132–45.PubMedCrossRefGoogle Scholar
  2. 2.
    Cunningham F, Leveno K, Bloom S, Hauth J, Rouse D, Spong C. Maternal physiology. Williams obstetrics. 23rd ed. New York: McGraw-Hill; 2010.Google Scholar
  3. 3.
    Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int. 1980;18(2):152–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Roberts M, Lindheimer MD, Davison JM. Altered glomerular permselectivity to neutral dextrans and heteroporous membrane modeling in human pregnancy. Am J Physiol. 1996;270(2 Pt 2):F338–43.PubMedGoogle Scholar
  5. 5.
    Higby K, Suiter CR, Phelps JY, Siler-Khodr T, Langer O. Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol. 1994;171(4):984–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Hou S. Pregnancy in chronic renal insufficiency and end-stage renal disease. Am J Kidney Dis. 1999;33(2):235–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004;5(3):266–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Saito S, Sakai M, Sasaki Y, Tanebe K, Tsuda H, Michimata T. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp Immunol. 1999;117(3):550–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Zen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S, et al. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly. 2010;140(13–14):187–201.PubMedGoogle Scholar
  10. 10.
    Andreoli L, Fredi M, Nalli C, Reggia R, Lojacono A, Motta M, et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun. 2012;38(2–3):J197–208.PubMedCrossRefGoogle Scholar
  11. 11.
    Clark CA, Spitzer KA, Laskin CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol. 2005;32(9):1709–12.PubMedGoogle Scholar
  12. 12.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.PubMedCrossRefGoogle Scholar
  14. 14.
    Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199(2):127 e1–6.CrossRefGoogle Scholar
  15. 15.
    Kong NC. Pregnancy of a lupus patient—a challenge to the nephrologist. Nephrol Dial Transplant. 2006;21(2):268–72.PubMedCrossRefGoogle Scholar
  16. 16.
    Wagner SJ, Craici I, Reed D, Norby S, Bailey K, Wiste HJ, et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus. 2009;18(4):342–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Ramsey-Goldman R, Kutzer JE, Kuller LH, Guzick D, Carpenter AB, Medsger Jr TA. Previous pregnancy outcome is an important determinant of subsequent pregnancy outcome in women with systemic lupus erythematosus. Am J Reprod Immunol. 1992;28(3–4):195–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum. 1992;35(1):55–61.PubMedCrossRefGoogle Scholar
  19. 19.
    Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–58.PubMedGoogle Scholar
  20. 20.
    Lindheimer MD, Davison JM. Renal biopsy during pregnancy: ‘to b.. or not to b.. ?’. Br J Obstet Gynaecol. 1987;94(10):932–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Schewitz LJ, Friedman IA, Pollak VE. Bleeding after renal biopsy in pregnancy. Obstet Gynecol. 1965;26:295–304.PubMedGoogle Scholar
  22. 22.
    Chen HH, Lin HC, Yeh JC, Chen CP. Renal biopsy in pregnancies complicated by undetermined renal disease. Acta Obstet Gynecol Scand. 2001;80(10):888–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Day C, Hewins P, Hildebrand S, Sheikh L, Taylor G, Kilby M, et al. The role of renal biopsy in women with kidney disease identified in pregnancy. Nephrol Dial Transplant. 2008;23(1):201–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Mintz G, Niz J, Gutierrez G, Garcia-Alonso A, Karchmer S. Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach. J Rheumatol. 1986;13(4):732–9.PubMedGoogle Scholar
  25. 25.
    Wong KL, Chan FY, Lee CP. Outcome of pregnancy in patients with systemic lupus erythematosus. A prospective study. Arch Intern Med. 1991;151(2):269–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. Lupus and pregnancy studies. Arthritis Rheum. 1993;36(10):1392–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Ruiz-Irastorza G, Lima F, Alves J, Khamashta MA, Simpson J, Hughes GR, et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol. 1996;35(2):133–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum. 1991;34(12):1538–45.PubMedCrossRefGoogle Scholar
  29. 29.
    Zulman JI, Talal N, Hoffman GS, Epstein WV. Problems associated with the management of pregnancies in patients with systemic lupus erythematosus. J Rheumatol. 1980;7(1):37–49.PubMedGoogle Scholar
  30. 30.
    Petri M. Pregnancy in SLE. Baillieres Clin Rheumatol. 1998;12(3):449–76.PubMedCrossRefGoogle Scholar
  31. 31.
    Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5(11):2060–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Ritchie J, Smyth A, Tower C, Helbert M, Venning M, Garovic VD. Maternal deaths in women with lupus nephritis: a review of published evidence. Lupus. 2012;21(5):534–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Brown CM, Garovic VD. Mechanisms and management of hypertension in pregnant women. Curr Hypertens Rep. 2011;13(5):338–46.PubMedCrossRefGoogle Scholar
  35. 35.
    Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus. 2006;15(3):148–55.PubMedCrossRefGoogle Scholar
  36. 36.
    Carmona F, Font J, Moga I, Lazaro I, Cervera R, Pac V, et al. Class III-IV proliferative lupus nephritis and pregnancy: a study of 42 cases. Am J Reprod Immunol. 2005;53(4):182–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Fraser FC, Fainstat TD. Production of congenital defects in the off-spring of pregnant mice treated with cortisone; progress report. Pediatrics. 1951;8(4):527–33.PubMedGoogle Scholar
  38. 38.
    Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology. 1995;51(1):45–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796–804.PubMedCrossRefGoogle Scholar
  40. 40.
    European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. Nephrol Dial Transplant. 2002;17 Suppl 4:50–5.Google Scholar
  41. 41.
    Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85(7):647–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am. 2007;33(2):237–52.PubMedCrossRefGoogle Scholar
  43. 43.
    Ostensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209.PubMedCrossRefGoogle Scholar
  44. 44.
    Chen W, Tang X, Liu Q, Fu P, Liu F, Liao Y, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235–44.PubMedCrossRefGoogle Scholar
  45. 45.
    Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A(6):1241–8.PubMedCrossRefGoogle Scholar
  46. 46.
    El Sebaaly Z, Charpentier B, Snanoudj R. Fetal malformations associated with mycophenolate mofetil for lupus nephritis. Nephrol Dial Transplant. 2007;22(9):2722.PubMedCrossRefGoogle Scholar
  47. 47.
    Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82(12):1698–702.PubMedCrossRefGoogle Scholar
  48. 48.
    McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol. 1991;49:193–280.PubMedCrossRefGoogle Scholar
  49. 49.
    do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol. 2010;116(6):1433–43.PubMedCrossRefGoogle Scholar
  50. 50.
    Ruffatti A, Tonello M, Cavazzana A, Bagatella P, Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res. 2009;123(3):482–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Stevenson RE, Burton OM, Ferlauto GJ, Taylor HA. Hazards of oral anticoagulants during pregnancy. JAMA. 1980;243(15):1549–51.PubMedCrossRefGoogle Scholar
  52. 52.
    Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):844S–86.PubMedCrossRefGoogle Scholar
  53. 53.
    Petri M. Hopkins Lupus Pregnancy Center: 1987 to 1996. Rheum Dis Clin North Am. 1997;23(1):1–13.PubMedCrossRefGoogle Scholar
  54. 54.
    Steen VD. Pregnancy in women with systemic sclerosis. Obstet Gynecol. 1999;94(1):15–20.PubMedCrossRefGoogle Scholar
  55. 55.
    Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42(1):42–55.PubMedCrossRefGoogle Scholar
  56. 56.
    Mouthon L, Berezne A, Bussone G, Noel LH, Villiger PM, Guillevin L. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy Immunol. 2011;40(2):84–91.PubMedCrossRefGoogle Scholar
  57. 57.
    Limardo M, Imbasciati E, Ravani P, Surian M, Torres D, Gregorini G, et al. Pregnancy and progression of IgA nephropathy: results of an Italian multicenter study. Am J Kidney Dis. 2010;56(3):506–12.PubMedCrossRefGoogle Scholar
  58. 58.
    Oh HJ, Han SH, Yoo DE, Kim SJ, Park JT, Kim JK, et al. Reduced pre-pregnancy proteinuria is associated with improving postnatal maternal renal outcomes in IgA nephropathy women. Clin Nephrol. 2011;76(6):447–54.PubMedGoogle Scholar
  59. 59.
    Abe S. The influence of pregnancy on the long-term renal prognosis of IgA nephropathy. Clin Nephrol. 1994;41(2):61–4.PubMedGoogle Scholar
  60. 60.
    Reece EA, Coustan DR, Gabbe SG. Diabetes in women: adolescence, pregnancy and menopause. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004.Google Scholar
  61. 61.
    Reece EA, Leguizamon G, Homko C. Pregnancy performance and outcomes associated with diabetic nephropathy. Am J Perinatol. 1998;15(7):413–21.PubMedCrossRefGoogle Scholar
  62. 62.
    Mackie AD, Doddridge MC, Gamsu HR, Brudenell JM, Nicolaides KH, Drury PL. Outcome of pregnancy in patients with insulin-dependent diabetes mellitus and nephropathy with moderate renal impairment. Diabet Med. 1996;13(1):90–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Combs CA, Rosenn B, Kitzmiller JL, Khoury JC, Wheeler BC, Miodovnik M. Early-pregnancy proteinuria in diabetes related to preeclampsia. Obstet Gynecol. 1993;82(5):802–7.PubMedGoogle Scholar
  64. 64.
    Hod M, van Dijk DJ, Karp M, Weintraub N, Rabinerson D, Bar J, et al. Diabetic nephropathy and pregnancy: the effect of ACE inhibitors prior to pregnancy on fetomaternal outcome. Nephrol Dial Transplant. 1995;10(12):2328–33.PubMedGoogle Scholar
  65. 65.
    Kitiyakara C, Kopp JB, Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23(2):172–82.PubMedCrossRefGoogle Scholar
  66. 66.
    USRDS 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States: national institutes of health. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2010.Google Scholar
  67. 67.
    D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398–411.PubMedCrossRefGoogle Scholar
  68. 68.
    Nagai Y, Arai H, Washizawa Y, Ger Y, Tanaka M, Maeda M, et al. FSGS-like lesions in pre-eclampsia. Clin Nephrol. 1991;36(3):134–40.PubMedGoogle Scholar
  69. 69.
    Banfi G, Moriggi M, Sabadini E, Fellin G, D’Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol. 1991;36(2):53–9.PubMedGoogle Scholar
  70. 70.
    Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America nephrotic syndrome study group. Kidney Int. 1999;56(6):2220–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Schonenberger E, Ehrich JH, Haller H, Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant. 2011;26(1):18–24.PubMedCrossRefGoogle Scholar
  72. 72.
    Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S, et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant. 2004;19(5):1288–92.PubMedCrossRefGoogle Scholar
  74. 74.
    Churchill D, Beevers GD, Meher S, Rhodes C. Diuretics for preventing pre-eclampsia. Cochrane Database Syst Rev. 2007;1, CD004451.PubMedGoogle Scholar
  75. 75.
    Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183(1):S1–22.Google Scholar
  76. 76.
    Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis. 1997;30(5):621–31.PubMedCrossRefGoogle Scholar
  77. 77.
    Meyrier A, Niaudet P. Minimal change and focal segmental glomerulosclerosis. In: Davison AM, Cameron JS, Grunfeld JP, Ponticelli C, Van Ypersele C, Ritz E, et al., editors. Oxford textbook of clinical nephrology. Oxford: Oxford University Press; 2005. p. 439.Google Scholar
  78. 78.
    Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952–60.PubMedCrossRefGoogle Scholar
  79. 79.
    Nakayama M, Katafuchi R, Yanase T, Ikeda K, Tanaka H, Fujimi S. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis. 2002;39(3):503–12.PubMedCrossRefGoogle Scholar
  80. 80.
    Leisti S, Koskimies O. Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression. J Pediatr. 1983;103(4):553–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Beck Jr LH, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.PubMedCrossRefGoogle Scholar
  82. 82.
    Seo P. Pregnancy and vasculitis. Rheum Dis Clin North Am. 2007;33(2):299–317.PubMedCrossRefGoogle Scholar
  83. 83.
    Suri V, Aggarwal N, Keepanasseril A, Chopra S, Vijayvergiya R, Jain S. Pregnancy and Takayasu arteritis: a single centre experience from North India. J Obstet Gynaecol Res. 2010;36(3):519–24.PubMedCrossRefGoogle Scholar
  84. 84.
    Koukoura O, Mantas N, Linardakis H, Hajiioannou J, Sifakis S. Successful term pregnancy in a patient with Wegener’s granulomatosis: case report and literature review. Fertil Steril. 2008;89(2):457 e1–5.CrossRefGoogle Scholar
  85. 85.
    Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol. 2004;93(4):398–401.PubMedCrossRefGoogle Scholar
  86. 86.
    Silva F, Specks U, Sethi S, Irazabal MV, Fervenza FC. Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis. Am J Kidney Dis. 2009;54(3):542–5.PubMedCrossRefGoogle Scholar
  87. 87.
    Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006;107(6):1219–26.PubMedCrossRefGoogle Scholar
  88. 88.
    Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–83.PubMedCrossRefGoogle Scholar
  89. 89.
    Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111(5):707–16.PubMedGoogle Scholar
  90. 90.
    Kincaid-Smith P, Fairley KF, Kloss M. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med. 1988;68(258):795–815.PubMedGoogle Scholar
  91. 91.
    Ihle BU, Long P, Oats J. Early onset pre-eclampsia: recognition of underlying renal disease. BMJ. 1987;294(6564):79–81.PubMedCrossRefGoogle Scholar
  92. 92.
    Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278(15):12605–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Garovic VD, Wagner SJ, Petrovic LM, Gray CE, Hall P, Sugimoto H, et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant. 2007;22(4):1136–43.PubMedCrossRefGoogle Scholar
  94. 94.
    Garovic VD, Wagner SJ, Turner ST, Rosenthal DW, Watson WJ, Brost BC, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol. 2007;196(4):320 e1–7.CrossRefGoogle Scholar
  95. 95.
    Aita K, Etoh M, Hamada H, Yokoyama C, Takahashi A, Suzuki T, et al. Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Pract. 2009;112(2):c65–70.PubMedCrossRefGoogle Scholar
  96. 96.
    Singh MM, Macgillivray I, Mahaffy RG. A study of the long-term effects of pre-eclampsia on blood pressure and renal function. J Obstet Gynaecol Br Commonw. 1974;81(11):903–6.PubMedCrossRefGoogle Scholar
  97. 97.
    Chesley SC, Annitto JE, Cosgrove RA. The remote prognosis of eclamptic women. Sixth periodic report. Am J Obstet Gynecol. 1976;124(5):446–59.PubMedGoogle Scholar
  98. 98.
    Garovic VD, Bailey KR, Boerwinkle E, Hunt SC, Weder AB, Curb JD, Mosley TH, Wiste JW, Turner ST. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens. 2010;28(4):826–33.Google Scholar
  99. 99.
    Bar J, Kaplan B, Wittenberg C, Erman A, Boner G, Ben-Rafael Z, et al. Microalbuminuria after pregnancy complicated by pre-eclampsia. Nephrol Dial Transplant. 1999;14(5):1129–32.PubMedCrossRefGoogle Scholar
  100. 100.
    Kattah AG, Asad R, Scantlebury DC, Bailey KR, Wiste HJ, Hunt SC, Mosley TH, Kardia SR, Turner ST, Garovic VD. Hypertension in Pregnancy is a Risk Factor for Microalbuminuria Later in Life. J Clin Hypertens 29 APR 013DOI: 10.1111/jch.12116.Google Scholar
  101. 101.
    Vikse BE, Irgens LM, Bostad L, Iversen BM. Adverse perinatal outcome and later kidney biopsy in the mother. J Am Soc Nephrol. 2006;17(3):837–45.PubMedCrossRefGoogle Scholar
  102. 102.
    Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med. 2008;359(8):800–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Heaton JM, Turner DR. Persistent renal damage following pre-eclampsia: a renal biopsy study of 13 patients. J Pathol. 1985;147(2):121–6.PubMedCrossRefGoogle Scholar
  104. 104.
    Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676–87.PubMedCrossRefGoogle Scholar
  105. 105.
    Fakhouri F, Roumenina L, Provot F, Sallee M, Caillard S, Couzi L, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859–67.PubMedCrossRefGoogle Scholar
  106. 106.
    Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISE cohort. PLoS Med. 2011;8(3):e1001013.PubMedCrossRefGoogle Scholar
  107. 107.
    Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M, et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood. 2008;112(12):4542–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.HRB Clinical Research Facility GalwayNational University of IrelandGalwayIreland
  2. 2.Division of Nephrology and HypertensionMayo Clinic College of MedicineRochesterUSA

Personalised recommendations